MAPT and Alzheimer disease: More recently, CSF measurement of the tau/amyloid β protein ratio has been shown to have a high sensitivity for diagnosis of AD but was not assessed in most of the cases in this series.15 Similarly, amyloid beta ligand PET was not in routine clinical use during the course of this study.